B+
Bull case
25%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
PHAT
PhathomDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-24
Recent news sentiment (30D)
-0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+61.6
Score
AI commentary
Litigation dominated the October 23 tape: PHAT fell approximately 18% from the prior close, though the packet's adjusted-close anchor is $5.74 and outside quotes differ slightly. https://chartexchange.com/symbol/nasdaq-phat/news/ The October 21 Craig-Hallum target cut predates the suit; Cantor's October 23 view is an initial reaction, not a resolved consensus. Social, options, short-interest, and employee measurements are unavailable; their zero fields must not be read as neutral observations.
RankAlpha Sentiment Codex - 2026-10-24
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-10-29catalystOctober 29 commercial updateHigh impact
The scheduled Q3 results should test VOQUEZNA prescription conversion, prior-authorization friction, and the moderated $310 million–$325 million 2026 revenue outlook. Q2 revenue was $74.3 million, up 88% year over year; that result does not establish Q3 performance. [#SEC-8K-2026-07-30] [#EARNINGS-TRANSCRIPT-2026Q2] https://investors.phathompharma.com/news-releases/news-release-details/phathom-pharmaceuticals-report-third-quarter-2026-financial
2026-12-31eventPhase 2 EoE topline resultsHigh impact
Phathom completed enrollment in pHalcon-EoE-201 and expects topline results from its blinded treatment period in Q4 2026. Positive data could support further FDA discussions, not an immediate approval. [#SEC-8K-2026-07-30] https://www.sec.gov/Archives/edgar/data/1783183/000119312526324865/d114879dex991.htm
2027-12-31eventVOQUEZNA exclusivity litigationHigh impact
BDR has sued the FDA over its refusal to receive a generic application referencing VOQUEZNA. Phathom says the FDA recognized exclusivity through May 3, 2032, but warns that an adverse outcome could permit earlier generic applications and competition. The timing and outcome are unknown. [#8-K-2026-10-23] https://www.sec.gov/Archives/edgar/data/1783183/000119312526430621/d437998d8k.htm
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-24 • Updated nightlySource: Internal modelMethodology